Squarepoint
DYN icon

Squarepoint’s Dyne Therapeutics DYN Stock Holding History

Squarepoint’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.66M Sell
300,074
-534,102
-64% -$9.93M 0.01% 1366
2026
Q1 		$15.1M Buy
834,176
+579,016
+227% +$9.98M 0.02% 849
2025
Q4 		$4.99M Buy
255,160
+207,568
+436% +$3.93M 0.01% 1453
2025
Q3 		$602K Sell
47,592
-134,148
-74% -$1.53M ﹤0.01% 3096
2025
Q2 		$1.73M Buy
181,740
+139,896
+334% +$1.54M ﹤0.01% 2204
2025
Q1 		$438K Sell
41,844
-9,772
-19% -$140K ﹤0.01% 3429
2024
Q4 		$1.22M Sell
51,616
-31,613
-38% -$935K ﹤0.01% 2874
2024
Q3 		$2.99M Buy
83,229
+38,033
+84% +$1.51M ﹤0.01% 1780
2024
Q2 		$1.59M Sell
45,196
-33,984
-43% -$988K ﹤0.01% 2214
2024
Q1 		$2.25M Buy
+79,180
New +$1.79M ﹤0.01% 2018
2023
Q3 		– Sell
-34,063
Closed -$383K – 3879
2023
Q2 		$383K Buy
34,063
+9,701
+40% +$114K ﹤0.01% 2807
2023
Q1 		$281K Buy
+24,362
New +$316K ﹤0.01% 2613
2020
Q4 		– Sell
-23,174
Closed -$468K – 2990
2020
Q3 		$468K Buy
+23,174
New +$509K 0.01% 1483

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Squarepoint's DYN Position: Q2 2026 in Review

Squarepoint reduced its Dyne Therapeutics (DYN) stake by 64% in Q2 2026, selling an estimated $9.93M and leaving 300,074 shares worth $6.66M. The position accounts for 0.01% of the portfolio, ranked #1366.

Squarepoint first reported a position in DYN in Q3 2020 and has held it in 13 quarters since. The position peaked at $15.1M in Q1 2026. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Squarepoint held 300,074 shares of Dyne Therapeutics worth $6.66M as of Q2 2026.
  • Squarepoint sold 534,102 Dyne Therapeutics shares in Q2 2026, an estimated $9.93M.
  • Dyne Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1366 holding.
  • Squarepoint first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 13 quarters since.
  • Squarepoint's Dyne Therapeutics position peaked at $15.1M in Q1 2026.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.